Brighton Jones LLC Acquires New Holdings in Evolent Health, Inc. (NYSE:EVH)

Brighton Jones LLC acquired a new position in shares of Evolent Health, Inc. (NYSE:EVH) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 349,109 shares of the technology company’s stock, valued at approximately $3,927,000. Brighton Jones LLC owned 0.30% of Evolent Health as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Covestor Ltd increased its position in shares of Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after purchasing an additional 1,556 shares during the last quarter. Quarry LP bought a new stake in shares of Evolent Health during the 2nd quarter worth approximately $32,000. Canada Pension Plan Investment Board acquired a new stake in shares of Evolent Health in the 2nd quarter valued at approximately $61,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its holdings in Evolent Health by 2,471.9% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,507 shares of the technology company’s stock worth $184,000 after buying an additional 6,254 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Needham & Company LLC initiated coverage on shares of Evolent Health in a research report on Friday, January 10th. They issued a “buy” rating and a $15.00 price objective for the company. Canaccord Genuity Group lowered their price target on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday. Truist Financial cut their price objective on shares of Evolent Health from $20.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday. JPMorgan Chase & Co. lowered their target price on shares of Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, November 22nd. Finally, Barclays reduced their price target on Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. One analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Evolent Health currently has a consensus rating of “Buy” and a consensus target price of $19.31.

Evolent Health Trading Up 1.6 %

Shares of EVH opened at $10.16 on Friday. Evolent Health, Inc. has a 12 month low of $9.74 and a 12 month high of $35.00. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The firm’s fifty day simple moving average is $11.50 and its two-hundred day simple moving average is $20.44.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, November 7th. The technology company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.30 by ($0.38). The company had revenue of $621.40 million for the quarter, compared to analyst estimates of $625.58 million. Evolent Health had a positive return on equity of 6.30% and a negative net margin of 2.93%. During the same period last year, the business earned $0.19 EPS. Equities analysts expect that Evolent Health, Inc. will post 0.26 earnings per share for the current year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.